Astellas Begins the P-III Clinical Evaluation of Fezolinetant for Vasomotor Symptoms (VMS) Among Breast Cancer Patients
Shots:
- Astellas has dosed the first patient in the P-III (HIGHLIGHT 1) trial of fezolinetant for VMS among breast cancer patients on adj. endocrine therapy
- The P-III (HIGHLIGHT 1) trial aims to evaluate the safety & efficacy of fezolinetant vs PBO to treat moderate to severe VMS among HR+ breast cancer women (n=540) on adj. endocrine therapy. Co-1EPs include changes in VMS frequency & severity at wks. 4 & 12, with treatment lasting 52wks. & final evaluation at 55wks.
- Fezolinetant (oral) is a nonhormonal therapy that inhibits the binding of neurokinin B (NKB) on KNDy neurons to re-establish balance in the hypothalamus, decreasing hot flashes and night sweats
Ref: Astellas | Image: Astellas
Related News:- Astellas Commences the P-III Evaluation of Fezolinetant for the Treatment of VMS Associated with Menopause in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
